Compare Novo Nordisk A/S (NVO) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Nextpower Inc. Common Stock — how do they compare? Novo Nordisk A/S trades at $38.68 (market cap $169.24B), while Nextpower Inc. Common Stock trades at $81 (market cap $12.53B). The key difference: Novo Nordisk A/S is far larger — about 13.5× Nextpower Inc. Common Stock's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Nextpower Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Nextpower Inc. Common Stock for 0 Days on average.
| NVO | NXT | |
|---|---|---|
Market Cap | $169.24B | $12.53B |
Volume | 9,314,273 | 3,195,746 |
Sector | Health | Energy |
52-Week High | $63.98 | $156.40 |
52-Week Low | $35.29 | $77.93 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $187.94B | $11.98B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.06, down 1.35% on the day, with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and 59.82% ROE, while recent quarterly earnings consistently beat expectations. Technical indicators show oversold conditions with RSI at 85.35, though the stock faces resistance at $39 levels. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews of hemophilia treatments.
NVO presents a compelling value opportunity with a 9.67 P/E ratio below industry averages and 58.98% analyst buy ratings targeting $42.33. Strong cash flow generation ($119.1B operating cash flow) supports dividend payments and strategic acquisitions. Key risks include competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays, but the company's dominant GLP-1 market position and expanding oral formulations provide growth catalysts.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
